We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
LPCN's Tlando provides a commercial foundation through royalties and expanding international opportunities.
Brlizio's phase III BLOOM study could provide key efficacy and safety data for postpartum depression.
LPCN's pipeline includes oral therapies for depression, obesity, epilepsy and liver cirrhosis.
Lipocine (LPCN - Free Report) is an emerging specialty pharmaceutical company focused on developing oral therapies for diseases with significant unmet medical needs. The company offers a mix of an approved commercial product, a potentially differentiated lead pipeline candidate and several early-stage programs that could support long-term growth.
LPCN’s Tlando Provides a Commercial Foundation
One of the key positives for Lipocine is Tlando, its oral testosterone replacement therapy. The FDA approved the drug in 2022 for adult males with testosterone deficiency, also known as hypogonadism.
The drug is commercialized through licensing partners across multiple territories. In the United States, Verity Pharma markets the product under an exclusive licensing agreement, while Lipocine receives royalties from sales.
The commercial opportunity is also expanding internationally. Tlando has received regulatory approval in markets, including the UAE, where it will be marketed as Testyra and Canada.
Lipocine also has licensing and distribution agreements covering markets such as Brazil, South Korea and the Gulf Cooperation Council countries. Additional geographic approvals and launches could provide further upside.
Over the past six months, shares of Lipocine have gained 5.2% against the industry’s 6.2% decline.
Image Source: Zacks Investment Research
LPCN 1154 Could Be LPCN’s Key Near-Term Catalyst
Beyond its commercial product, Brlizio (LPCN 1154) represents an important potential value driver. The candidate is an oral formulation of brexanolone being developed for postpartum depression.
Brlizio is designed as a 48-hour, at-home oral treatment, which could offer greater convenience than treatment approaches requiring prolonged administration or intensive medical supervision. Lipocine believes the product could provide rapid symptom relief while maintaining a favorable tolerability profile.
However, the program carries significant clinical risk. An earlier late-stage study failed to meet its primary endpoint in the full analysis set. Lipocine later identified data anomalies at one high-enrolling site. A post hoc analysis excluding that site showed rapid and sustained improvement in depression symptoms.
To further evaluate the candidate, Lipocine initiated the phase III BLOOM study in September 2026, with patient dosing expected to initiate in early fourth quarter of 2026. The new study is designed to provide additional efficacy and safety data under strengthened study controls.
Positive results could serve as an important catalyst for LPCN and strengthen the development case for Brlizio.
The company has several early-stage programs targeting different therapeutic areas, including LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 1148 for liver cirrhosis, LPCN 2401 for obesity management and LPCN 1107 for prevention of preterm birth.
Among these programs, LPCN 2201 could provide another opportunity to leverage the company's oral brexanolone technology. Lipocine plans to submit a phase II study protocol to the FDA and may initiate a study evaluating LPCN 2201 in major depressive disorder.
LPCN 2401 could provide exposure to the large obesity market. The company is developing it as an oral therapy that could potentially be used alongside GLP-1 therapies or after patients discontinue GLP-1 treatment. Pending regulatory guidance, Lipocine may advance the candidate into a phase II proof-of-concept study in older overweight and obese patients, while also exploring potential partnerships.
Over the past 60 days, estimates for LPCN’s 2026 loss per share have narrowed from $1.91 to $1.54.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) , currently sporting a Zacks Rank #1 each andAldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 13.9% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 81.5% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Key Takeaways
Lipocine (LPCN - Free Report) is an emerging specialty pharmaceutical company focused on developing oral therapies for diseases with significant unmet medical needs. The company offers a mix of an approved commercial product, a potentially differentiated lead pipeline candidate and several early-stage programs that could support long-term growth.
LPCN’s Tlando Provides a Commercial Foundation
One of the key positives for Lipocine is Tlando, its oral testosterone replacement therapy. The FDA approved the drug in 2022 for adult males with testosterone deficiency, also known as hypogonadism.
The drug is commercialized through licensing partners across multiple territories. In the United States, Verity Pharma markets the product under an exclusive licensing agreement, while Lipocine receives royalties from sales.
The commercial opportunity is also expanding internationally. Tlando has received regulatory approval in markets, including the UAE, where it will be marketed as Testyra and Canada.
Lipocine also has licensing and distribution agreements covering markets such as Brazil, South Korea and the Gulf Cooperation Council countries. Additional geographic approvals and launches could provide further upside.
Over the past six months, shares of Lipocine have gained 5.2% against the industry’s 6.2% decline.
Image Source: Zacks Investment Research
LPCN 1154 Could Be LPCN’s Key Near-Term Catalyst
Beyond its commercial product, Brlizio (LPCN 1154) represents an important potential value driver. The candidate is an oral formulation of brexanolone being developed for postpartum depression.
Brlizio is designed as a 48-hour, at-home oral treatment, which could offer greater convenience than treatment approaches requiring prolonged administration or intensive medical supervision. Lipocine believes the product could provide rapid symptom relief while maintaining a favorable tolerability profile.
However, the program carries significant clinical risk. An earlier late-stage study failed to meet its primary endpoint in the full analysis set. Lipocine later identified data anomalies at one high-enrolling site. A post hoc analysis excluding that site showed rapid and sustained improvement in depression symptoms.
To further evaluate the candidate, Lipocine initiated the phase III BLOOM study in September 2026, with patient dosing expected to initiate in early fourth quarter of 2026. The new study is designed to provide additional efficacy and safety data under strengthened study controls.
Positive results could serve as an important catalyst for LPCN and strengthen the development case for Brlizio.
Lipocine Inc. Price and Consensus
Lipocine Inc. price-consensus-chart | Lipocine Inc. Quote
LPCN’s Broader Pipeline Adds Long-Term Upside
The company has several early-stage programs targeting different therapeutic areas, including LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 1148 for liver cirrhosis, LPCN 2401 for obesity management and LPCN 1107 for prevention of preterm birth.
Among these programs, LPCN 2201 could provide another opportunity to leverage the company's oral brexanolone technology. Lipocine plans to submit a phase II study protocol to the FDA and may initiate a study evaluating LPCN 2201 in major depressive disorder.
LPCN 2401 could provide exposure to the large obesity market. The company is developing it as an oral therapy that could potentially be used alongside GLP-1 therapies or after patients discontinue GLP-1 treatment. Pending regulatory guidance, Lipocine may advance the candidate into a phase II proof-of-concept study in older overweight and obese patients, while also exploring potential partnerships.
LPCN's Zacks Rank & Estimates
Lipocinecurrently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for LPCN’s 2026 loss per share have narrowed from $1.91 to $1.54.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) , currently sporting a Zacks Rank #1 each andAldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 13.9% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 81.5% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.